QQQ   387.18 (-0.42%)
AAPL   190.35 (+0.21%)
MSFT   372.40 (-1.72%)
META   321.55 (-1.71%)
GOOGL   130.93 (-1.21%)
AMZN   146.16 (+0.05%)
TSLA   234.67 (-2.25%)
NVDA   465.10 (-0.56%)
NIO   7.07 (-2.75%)
BABA   72.73 (-2.87%)
AMD   119.91 (-1.03%)
T   16.65 (+0.48%)
F   10.44 (+1.75%)
MU   76.10 (-0.03%)
CGC   0.57 (+2.23%)
GE   122.91 (+0.91%)
DIS   92.20 (-0.53%)
AMC   6.76 (+1.65%)
PFE   28.95 (-4.99%)
PYPL   58.16 (+0.95%)
XOM   103.67 (+0.91%)
QQQ   387.18 (-0.42%)
AAPL   190.35 (+0.21%)
MSFT   372.40 (-1.72%)
META   321.55 (-1.71%)
GOOGL   130.93 (-1.21%)
AMZN   146.16 (+0.05%)
TSLA   234.67 (-2.25%)
NVDA   465.10 (-0.56%)
NIO   7.07 (-2.75%)
BABA   72.73 (-2.87%)
AMD   119.91 (-1.03%)
T   16.65 (+0.48%)
F   10.44 (+1.75%)
MU   76.10 (-0.03%)
CGC   0.57 (+2.23%)
GE   122.91 (+0.91%)
DIS   92.20 (-0.53%)
AMC   6.76 (+1.65%)
PFE   28.95 (-4.99%)
PYPL   58.16 (+0.95%)
XOM   103.67 (+0.91%)
QQQ   387.18 (-0.42%)
AAPL   190.35 (+0.21%)
MSFT   372.40 (-1.72%)
META   321.55 (-1.71%)
GOOGL   130.93 (-1.21%)
AMZN   146.16 (+0.05%)
TSLA   234.67 (-2.25%)
NVDA   465.10 (-0.56%)
NIO   7.07 (-2.75%)
BABA   72.73 (-2.87%)
AMD   119.91 (-1.03%)
T   16.65 (+0.48%)
F   10.44 (+1.75%)
MU   76.10 (-0.03%)
CGC   0.57 (+2.23%)
GE   122.91 (+0.91%)
DIS   92.20 (-0.53%)
AMC   6.76 (+1.65%)
PFE   28.95 (-4.99%)
PYPL   58.16 (+0.95%)
XOM   103.67 (+0.91%)
QQQ   387.18 (-0.42%)
AAPL   190.35 (+0.21%)
MSFT   372.40 (-1.72%)
META   321.55 (-1.71%)
GOOGL   130.93 (-1.21%)
AMZN   146.16 (+0.05%)
TSLA   234.67 (-2.25%)
NVDA   465.10 (-0.56%)
NIO   7.07 (-2.75%)
BABA   72.73 (-2.87%)
AMD   119.91 (-1.03%)
T   16.65 (+0.48%)
F   10.44 (+1.75%)
MU   76.10 (-0.03%)
CGC   0.57 (+2.23%)
GE   122.91 (+0.91%)
DIS   92.20 (-0.53%)
AMC   6.76 (+1.65%)
PFE   28.95 (-4.99%)
PYPL   58.16 (+0.95%)
XOM   103.67 (+0.91%)

Bellicum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BLCM)

$0.24
+0.02 (+7.50%)
(As of 09:33 AM ET)
Compare
Today's Range
$0.24
$0.24
50-Day Range
$0.10
$0.48
52-Week Range
$0.06
$1.50
Volume
660 shs
Average Volume
845,284 shs
Market Capitalization
$2.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BLCM stock logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

BLCM Stock Price History

BLCM Stock News Headlines

Futura Medical plc (FAMDF)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
BLCM - Bellicum Pharmaceuticals, Inc.
Short Volatility Alert: Bellicum Pharma
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Why Bellicum Pharmaceuticals Stock Is Plunging Today
BLCM Bellicum Pharmaceuticals, Inc.
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
11/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-24,970,000.00
Pretax Margin
-1,492.40%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
($2.84) per share

Miscellaneous

Free Float
8,518,000
Market Cap
$2.13 million
Optionable
Not Optionable
Beta
1.36
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Charles S. Grass (Age 63)
    Principal Accounting Officer
  • Mr. Joseph Senesac (Age 53)
    Senior Vice President of Technical Operations & Quality
  • Dr. Alan K. Smith Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $536.43k














BLCM Stock Analysis - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
View BLCM analyst ratings
or view top-rated stocks.

How have BLCM shares performed in 2023?

Bellicum Pharmaceuticals' stock was trading at $0.72 at the start of the year. Since then, BLCM shares have decreased by 66.6% and is now trading at $0.2408.
View the best growth stocks for 2023 here
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) announced its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $1 million for the quarter.

When did Bellicum Pharmaceuticals' stock split?

Bellicum Pharmaceuticals's stock reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BLCM) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -